Potential for biotech growth in Øresund region  

2006.01.27
The Øresund region cemented its leading status in the medico and biotech industry in 2005. Director Mette Kirstine Agger of 7TM Pharma sees potential for further growth in the region

In 2005, the Øresund region cemented its leading status in the medico and biotech industry. The numbers of biotech companies have grown steadily in recent years, and director Mette Kirstine Agger of 7TM Pharma in Hørsholm sees potential for further growth in R&D of drugs in the region.

"There is a great interest in Danish biotech industry, and at 7TM Pharma we have had a really good year with fine results in research and raising of capital. There is a favourable concentration of university environments, hospitals and pharmaceutical industry in the Øresund region, and we are looking very positively on developments in 2006 especially in line with the total increased knowledge base which has been built over the years", says Mette Kirstine Agger, who was part of founding 7TM Pharma in 2000.

7TM Pharma is a drug discovery and development company which has a pipeline of advanced programmes in its main therapeutic focus area, obesity. The biotech company's pipeline also includes programmes on well validated targets in allergy/inflammation, therapeutic angiogenesis and cardiovascular diseases. Last year, 7TM entered research agreements with Procter & Gamble Pharmaceuticals and Johnson & Johnson. The news was reported by the business newspaper, EhvervsAvisen.

Link > 7TM Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×